Literature DB >> 18490011

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Hanna Rosenmann1, Nikolaos Grigoriadis, Hila Eldar-Levy, Avi Avital, Lea Rozenstein, Olga Touloumi, Leah Behar, Tamir Ben-Hur, Yosefa Avraham, Eliot Berry, Menahem Segal, Irith Ginzburg, Oded Abramsky.   

Abstract

The neurofibrillary-tangles (NTFs), characteristic of tauopathies including Alzheimer's-disease (AD), are the pathological features which correlate best with dementia. The objective of our study was to generate an authentic transgenic (tg) animal model for NFT pathology in tauopathy/AD. Previous NFT-tg mice were driven by non-related/non-homologous promoters. Our strategy was to use the natural tau promoter for expressing the human-tau (htau) gene with two mutations K257T/P301S (double mutant, DM) associated with severe phenotypes of frontotemporal-dementia in humans. Cellular, biochemical, behavioral and electrophysiological studies were subsequently conducted. The tg mice showed a tolerated physiological level of the DM-htau protein, mostly in cortex and hippocampus. The mice demonstrated tauopathy-like characteristics, which increased with age, that included NFT-related pathology, astrogliosis, argyrophilic plaque-like (amyloid-free) structures in brain, with memory deficits and signs of anxiety. Moreover, the tg mice showed a robust synaptic plasticity deficit selectively expressed in a severe impairment in their ability to maintain hippocampal long-term-potentiation (LTP) in response to stimulation of the perforant path, providing evidence that "tau-pathology only" is sufficient to cause this memory and learning-associated deficit. This is a unique mutant-htau-tg model which presents a wide spectrum of features characteristic of tauopathy/AD, which does not show unrelated motor deficits described in other models of tauopathy. In addition, expressing the DM-htau in a neuronal cell model resulted in tau-aggregation, as well as impaired microtubule arrangement. Both animal and cell models, which were regulated under the natural tau promoter (of rat origin), provide authentic and reliable models for tauopathy, and offer valuable tools for understanding the molecular events underlying tauopathies including AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490011     DOI: 10.1016/j.expneurol.2008.03.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  37 in total

Review 1.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

Review 2.  Modulation and detection of tau aggregation with small-molecule ligands.

Authors:  Edward Chang; Nicolette S Honson; Bhaswati Bandyopadhyay; Kristen E Funk; Jordan R Jensen; Sohee Kim; Swati Naphade; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 3.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

Review 4.  Probing the biology of Alzheimer's disease in mice.

Authors:  Karen H Ashe; Kathleen R Zahs
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

5.  MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance.

Authors:  Beatriz E García-Gómez; Francisco J Fernández-Gómez; Encarnación Muñoz-Delgado; Luc Buée; David Blum; Cecilio J Vidal
Journal:  J Mol Neurosci       Date:  2015-12-23       Impact factor: 3.444

6.  Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model.

Authors:  Astrid Sydow; Ann Van der Jeugd; Fang Zheng; Tariq Ahmed; Detlef Balschun; Olga Petrova; Dagmar Drexler; Lepu Zhou; Gabriele Rune; Eckhard Mandelkow; Rudi D'Hooge; Christian Alzheimer; Eva-Maria Mandelkow
Journal:  J Mol Neurosci       Date:  2011-08-06       Impact factor: 3.444

Review 7.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer's disease.

Authors:  Yair Fisher; Anna Nemirovsky; Rona Baron; Alon Monsonego
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

Review 9.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

10.  Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.

Authors:  Dave Morgan; Sanjay Munireddy; Jennifer Alamed; Jason DeLeon; David M Diamond; Paula Bickford; Michael Hutton; Jada Lewis; Eileen McGowan; Marcia N Gordon
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.